Addressing Transgender Erasure in HIV Clinical Trials
The Scorecard for Transgender and Gender-Diverse Inclusion
Bibliographic Data
| ID | 11034461 |
|---|---|
| Authors | Brian Minalga (0000-0002-8447-390X, Brian Minalga is with the Office of HIV/AIDS Network Coordination, Fred Hutchinson Cancer Center, Seattle, WA. Cindra Feuer is with AVAC, New York, NY.), Cindra Feuer (Brian Minalga is with the Office of HIV/AIDS Network Coordination, Fred Hutchinson Cancer Center, Seattle, WA. Cindra Feuer is with AVAC, New York, NY.) |
| Year | 2025 |
| Volume | 115 |
| Issue | 10 |
| Pages | 1621-1630 |
| Publication date | 2025-10-01 |
| Open Access | No |
| Type | ARTICLE |
| Venue | American Journal of Public Health (JOURNAL) |
| Journal identifiers | ISSN: 0090-0036 • E-ISSN: 1541-0048 |
| Publisher | American Public Health Association (PUBLISHER • US) |
| DOI | 10.2105/ajph.2025.308134 |
| PMID | 40773733 |
| OpenAlex | W4413050517 |
| Language | EN |
| Citations received | 1 |
| References cited | 8 |
We sought to offer a structured framework for evaluating transgender and gender-diverse (TGD) inclusion in HIV clinical trials, with actionable criteria for trial design and conduct, and to quantify and characterize TGD inclusion in pivotal HIV studies as supporting evidence of the need for this framework. We devised a tool (scorecard) consisting of 14 scoreable indicators for TGD-responsive HIV research with input from global TGD communities. We tested the scorecard in a cross-sectional review of 41 randomized controlled HIV biomedical efficacy trials to measure TGD responsiveness. Studies were selected to represent the spectrum of groundbreaking HIV therapeutic and prevention studies enrolling participants in countries around the world from 1991 to 2023. We found that TGD individuals represent a reported 2532 (1.4%) of 178 893 participants in the selected HIV clinical trials. Scorecard indicators reveal a dearth of HIV research responsive to the needs of TGD communities. The lack of TGD representation in HIV clinical trials indicates a historical erasure of TGD communities with potential public health consequences. The scorecard might guide future HIV research to be more responsive to the needs of TGD people. ( Am J Public Health. 2025;115(10):1621–1630. https://doi.org/10.2105/AJPH.2025.308134 )
Erasure · Family medicine · Human immunodeficiency virus (HIV) · Inclusion (mineral) · Men who have sex with men · Sociology · Syphilis · Transgender · Transgender people · Transgender Person · Transgender women · Clinical Psychology · Computer Science · Gender Studies · HIV/AIDS Research and Interventions · LGBTQ Health, Identity, and Policy · Medicine · Psychology · Reproductive Health and Technologies · Social Psychology · Gerontology
| Citations per year | 1 |
|---|---|
| Citation span | 2026 - 2026 (1) |
| Highly cited | No |